Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, Jan. 18 '26)

Image
By G.M.

 


    Antiviral Res

  1. LEEKHA A, Reichel K, Hurst B, Varadarajan N, et al
    Therapeutic intranasal delivery of NanoSTING provides broad protection against seasonal and highly pathogenic influenza strains.
    Antiviral Res. 2026 Jan 14:106342. doi: 10.1016/j.antiviral.2026.106342.
    PubMed         Abstract available


    BMJ

  2. MARTIN DS, Doidge JC, Gould D, Shahid T, et al
    The impact of skin tone on performance of pulse oximeters used by NHS England COVID Oximetry @home scheme: measurement and diagnostic accuracy study.
    BMJ. 2026;392:e085535.
    PubMed         Abstract available


    Drug Saf

  3. PALMER M, Seekins D, Avigan M, Marcinak J, et al
    The Impact of COVID-19 and COVID-19 Vaccination on Detection, Assessment, and Management of Suspected Acute Drug-Induced Liver Injury Occurring during Clinical Trials: Consensus Recommendations from the IQ DILI Initiative.
    Drug Saf. 2026;49:9-25.
    PubMed         Abstract available


    Epidemiol Infect

  4. WOLMUTH-GORDON HS, Elgohari S, Dabrera G, Green RE, et al
    Estimating influenza A subtype ratios among critical care admissions in England.
    Epidemiol Infect. 2026 Jan 12:1-8. doi: 10.1017/S0950268825100812.
    PubMed        

  5. KOKAVECZ L, Sohajda Z, David P, Stagel A, et al
    Incidence of parvovirus B19 among Hungarian blood donor population during COVID-19 restrictions and the subsequent B19 epidemic of 2024.
    Epidemiol Infect. 2026;154:e11.
    PubMed         Abstract available

  6. BEJKO D, Vergison A, Stranges S, Mossong J, et al
    Protection from second booster vaccines and natural immunity against SARS-CoV-2 infections, 2022-2023.
    Epidemiol Infect. 2025;154:e10.
    PubMed         Abstract available

  7. CAREY C, O'Moore E, Huyton R, Willner S, et al
    COVID-19 outbreaks in care homes: How does size influence transmission dynamics? A cross-sectional study with implications for outbreak management in small care homes.
    Epidemiol Infect. 2025;154:e8.
    PubMed         Abstract available


    J Clin Microbiol

  8. BIGAUD B, Marjanovic N, Deroche L, Drugeon B, et al
    Impact of multiplex PCR point-of-care platform implementation for respiratory pathogen detection in an emergency department with high daily patient volume.
    J Clin Microbiol. 2026;64:e0131325.
    PubMed         Abstract available


    J Gen Virol

  9. GERODEZ A, Dufrasne FE, Denis O, Steensels M, et al
    The cellular activating protein-1 cFos regulates influenza A virus replication.
    J Gen Virol. 2026;107:002194.
    PubMed         Abstract available


    J Infect Dis

  10. SKOWRONSKI DM, Ranadheera C, Kaweski SE, Sabaiduc S, et al
    Cross-reactive H5N1 neuraminidase antibodies by age and influenza A imprinting cohorts of the past century: population-based serosurvey, British Columbia, Canada.
    J Infect Dis. 2026 Jan 16:jiag030. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  11. CONG G, Li H, Li L, Chen J, et al
    The newly developed porcine-origin parainfluenza virus PIV5-JS17 serves as an exogenous gene delivery system for swine.
    J Virol. 2026 Jan 13:e0185825. doi: 10.1128/jvi.01858.
    PubMed         Abstract available


    J Virol Methods

  12. ZHANG W, Chen XY, Lin SX
    Search and prove of efficient inhibitors against papain-like protease from SARS-CoV-2.
    J Virol Methods. 2026;341:115329.
    PubMed         Abstract available

  13. EPTAMINITAKI GC, Zafiropoulos A, Sourvinos G
    Evaluation of summation operator-MM molecular medium for the SARS-CoV-2 RNA stability over 90 days under different temperature conditions.
    J Virol Methods. 2026;341:115322.
    PubMed         Abstract available


    JAMA

  14. MCCLYMONT E, Blitz S, Forward L, Cole S, et al
    The Role of Vaccination in Maternal and Perinatal Outcomes Associated With COVID-19 in Pregnancy.
    JAMA. 2025 Dec 15:e2521001. doi: 10.1001/jama.2025.21001.
    PubMed         Abstract available


    N Engl J Med

  15. LAMPERT R, Harmon KG
    Sudden Cardiac Arrest in Athletes.
    N Engl J Med. 2026;394:268-280.
    PubMed         Abstract available


    Pediatrics

  16. HAMDAN O, Amarin JZ, Antoon JW, Stopczynski T, et al
    Influenza Antiviral Use in Hospitalized Children Before and During the COVID-19 Pandemic.
    Pediatrics. 2026 Jan 14:e2025071898. doi: 10.1542/peds.2025-071898.
    PubMed         Abstract available


    PLoS Comput Biol

  17. WANG Z, Zhou Z, Wang J, Yang L, et al
    Characterization of the heterogeneity in SARS-CoV-2 fitness dynamics via graph representation learning.
    PLoS Comput Biol. 2026;22:e1013582.
    PubMed         Abstract available

  18. MAYER-BLACKWELL K, Minervina A, Pogorelyy M, Rawat P, et al
    TCR2HLA: Calibrated inference of HLA genotypes from TCR repertoires enables identification of immunologically relevant metaclonotypes.
    PLoS Comput Biol. 2026;22:e1013767.
    PubMed         Abstract available


    PLoS One

  19. ORSOLIC BESLIC A, Caljkusic K, Matana A, Tomelic Ercegovic K, et al
    Evaluation of cerebrovascular reactivity using transcranial Doppler in patients with influenza.
    PLoS One. 2026;21:e0340768.
    PubMed         Abstract available

  20. SCHNEIDER JL, Rivelli JS, Escaron AL, Crocker R, et al
    Impact of COVID-19 on colorectal cancer screening in a federally qualified health center: Provider and staff perspectives.
    PLoS One. 2026;21:e0340184.
    PubMed         Abstract available

  21. VINER RM, Pearce A, Hope S
    The impact of school absence on mental health in children and young people: Analysis of an English national birth cohort.
    PLoS One. 2026;21:e0336137.
    PubMed         Abstract available

  22. MANN H, Dimon E, Zhang Y, Arroyo N, et al
    Impact of COVID-19 restrictions on thyroid cancer diagnoses in a comprehensive cancer center (2017-2023).
    PLoS One. 2026;21:e0340347.
    PubMed         Abstract available

  23. ZENG Z, Sathasivam S, Xin J, Zhao H, et al
    Public participation in healthcare safety: A tripartite evolutionary game model with evidence from diverse international cases.
    PLoS One. 2026;21:e0339304.
    PubMed         Abstract available

  24. RIBEIRO HS, Mondini DR, Santa-Catharina GP, Marcal L, et al
    Skeletal muscle-kidney crosstalk in a cohort of critical illness survivors.
    PLoS One. 2026;21:e0339795.
    PubMed         Abstract available

  25. BAI Y, Cao P, Kim C, Ienciu K, et al
    Longitudinal trends in vaping, smoking, and harmful alcohol use across sexual orientations in the UK (2014-2021).
    PLoS One. 2026;21:e0339847.
    PubMed         Abstract available

  26. AKTER N, Zerin FF, Banu B, Kanta FA, et al
    Quality of life in hypertensive patients using the WHOQOL-BREF instrument in the post-pandemic Bangladesh: A cross-sectional study.
    PLoS One. 2026;21:e0340897.
    PubMed         Abstract available


    Vaccine

  27. DE WALS P, Papenburg J, Gilca R, Brousseau N, et al
    Are hemagglutinin-only influenza vaccines as effective as conventional influenza vaccines against severe infection?
    Vaccine. 2026;74:128234.
    PubMed        

  28. CHENG K, Pullenayegum E, Singh P, Loeb M, et al
    Use of composite outcomes in cluster randomized control trials of influenza vaccines.
    Vaccine. 2026;74:128224.
    PubMed         Abstract available

  29. PAGE CL, Holbrook BC, Miller LD, Grayson JM, et al
    TLR5 versus TLR7/8 agonist-dependent modulation of the early gene expression response to inactivated influenza virus vaccine in newborn nonhuman primates.
    Vaccine. 2026;74:128163.
    PubMed         Abstract available

  30. HARKER EJ, Lewis NM, Johnson CA, Zhu Y, et al
    Differences in influenza vaccine effectiveness by sex among adults hospitalized with acute respiratory illness-IVY network, January 24, 2022-September 1, 2024.
    Vaccine. 2026;74:128192.
    PubMed         Abstract available

  31. DE BRABANDERE L, Herzog SA, Desombere I, Arien KK, et al
    Enhanced immune responses to mRNA compared with adenoviral vector COVID-19 vaccines during pregnancy: implications for pandemic preparedness.
    Vaccine. 2026;73:128153.
    PubMed         Abstract available

  32. ORELLANA-MANZANO A, Garcia-Angulo A, Quinto F, Munizaga MG, et al
    COVID-19 vaccination campaign, knowledge, and trust in Duran, Ecuador: a cross-sectional study.
    Vaccine. 2026;72:127867.
    PubMed         Abstract available

  33. YE G, Qu C, Liao Z, Wu R, et al
    Engineered flagellin-based adjuvant boosts mucosal immunity in recombinant RSV vaccine.
    Vaccine. 2026;73:128190.
    PubMed         Abstract available

  34. ZHU Z, Chen Z, Gao Y, Xie Z, et al
    Genetic distance predicts neutralizing antibody titers for monovalent and bivalent SARS-CoV-2 vaccines.
    Vaccine. 2026;73:128185.
    PubMed         Abstract available

  35. BREZNIK JA, Ang JC, Bhakta H, Liu LM, et al
    Humoral and cellular immunogenicity of sequential heterogeneous bivalent SARS-CoV-2 vaccinations in long-term care and retirement home residents.
    Vaccine. 2025;73:128160.
    PubMed         Abstract available

  36. OKABE H, Hashimoto K, Asano Y, Sato M, et al
    Adverse events post-BNT162b2 vaccination in Japanese children.
    Vaccine. 2025;73:128167.
    PubMed         Abstract available

  37. DANIEL N, Smith C, Miah N, Akroyd C, et al
    Enablers and barriers to participation in vaccine trials: a narrative synthesis.
    Vaccine. 2025;73:128183.
    PubMed         Abstract available

  38. REITER PL, Katz ML
    Vaccine hesitancy among midlife and older adults in the United States.
    Vaccine. 2025;72:128054.
    PubMed         Abstract available

  39. BALLOUT S, Darwish SA, Kelly PJ, Keller T, et al
    The use of storytelling in COVID-19 vaccine promotion: A scoping review of interventions and campaigns.
    Vaccine. 2025;72:128098.
    PubMed         Abstract available

  40. PARIDANS M, Gillain N, Husson E, Darcis G, et al
    COVID-19 vaccination: Does knowledge of higher immunity influence first and second COVID-19 booster uptake? A study carried out in a university population.
    Vaccine. 2025;72:128057.
    PubMed         Abstract available

  41. PAL SS, Kim KH, Bhatnagar N, Grovenstein P, et al
    A combination of new prefusion mRNA and protein vaccines enhances neutralizing antibodies and protection against respiratory syncytial virus.
    Vaccine. 2025;73:128154.
    PubMed         Abstract available

  42. ALVES K, Kouassi A, Nelson J, Plested JS, et al
    Safety and immunogenicity of a single dose of a JN.1 variant COVID-19 vaccine in previously vaccinated adults: Primary analysis report of a phase 3 open-label trial.
    Vaccine. 2025;73:128164.
    PubMed         Abstract available

  43. MIRON E, Sauvageau C, Dube E, Vivion M, et al
    Vaccine hesitancy among older adults, urban indigenous and newcomers in Canada: A qualitative comparative study.
    Vaccine. 2025;73:128143.
    PubMed         Abstract available

  44. STRENG BMM, Hensen LCM, Delemarre EM, Binnendijk RS, et al
    Antibody concentration and function following SARS-CoV-2 vaccination decrease with age in adults and children with Down syndrome.
    Vaccine. 2025;73:128079.
    PubMed         Abstract available

  45. LARSEN FD, Juhl AK, Dietz LL, Nielsen H, et al
    Immunogenicity of SARS-CoV-2 primary vaccination and boosters in patients with immune-mediated inflammatory diseases: Impact of immunosuppressive therapy.
    Vaccine. 2025;73:128155.
    PubMed         Abstract available

  46. SEESKIN ZH, Steffan M, Geistwhite B, Yarbrough M, et al
    Using latent class analysis of survey data to explore parent behaviors and attitudes regarding children's COVID vaccinations.
    Vaccine. 2025;73:128149.
    PubMed         Abstract available

  47. TIPTON T, Laidlaw S, Nguyen D, Longet S, et al
    ACE2 inhibition ELISA is an effective surrogate for SARS-CoV-2 live virus neutralisation.
    Vaccine. 2026;72:128123.
    PubMed         Abstract available

  48. KOVACS D, Brar G, Anthony SJ, Wang LF, et al
    Initiation of a coronavirus vaccine library.
    Vaccine. 2025;72:128140.
    PubMed         Abstract available

  49. HARO SLY MJ, Zubeldia L
    COVID-19 vaccine production and the technological gap in the Global South: The cases of Argentina and Brazil.
    Vaccine. 2025;72:128141.
    PubMed         Abstract available

  50. JABBAR F, Kadhim KA, Alhilfi RA, Al Khafaji IS, et al
    Advancements in monitoring adverse events following immunization in Iraq: Insights from the CIVIE project 2022-2023.
    Vaccine. 2026;72:128121.
    PubMed         Abstract available

  51. SINCLAIR JE, Mayfield HJ, Lu H, Brown SJ, et al
    Estimating risk of long COVID using a Bayesian network-based decision support tool.
    Vaccine. 2026;72:128127.
    PubMed         Abstract available

  52. DRISLANE S, Moore H, Attwell K
    Understanding parental decisions to decline or delay infant RSV immunisation, nirsevimab, in Western Australia in 2024.
    Vaccine. 2026;72:128133.
    PubMed         Abstract available

  53. MADIA JE, Nicodemo C, Petrou S, de Lusignan S, et al
    Primary healthcare costs associated with the AstraZeneca COVID-19 vaccine in England.
    Vaccine. 2025;72:128067.
    PubMed         Abstract available

  54. HAYASHI K, Hashimoto N, Hashimoto C, Takeuchi Y, et al
    Effect of completed COVID-19 vaccination on serum interferon lambda3: a single-center retrospective study.
    Vaccine. 2025;72:128108.
    PubMed         Abstract available


    Virology

  55. THOMAS MH, Carlock MA, Ross TM
    Adjuvants enhance protective antibodies against seasonal influenza viruses following a single vaccination of Fluzone.
    Virology. 2026;616:110787.
    PubMed         Abstract available

  56. IINO Y, Sato K, Furuse Y, Isogai E, et al
    Human parainfluenza virus type 3 viruses with the furin-susceptible motif at the cleavage site of the fusion protein arose from original wild strains during their propagation in vitro.
    Virology. 2026;617:110797.
    PubMed         Abstract available


    Virus Res

  57. CAI H, Hou L, Chang J, Yang Q, et al
    Venenum bufonis and its active constituents alleviate RSV-induced pneumonia in mice by suppressing macrophage infiltration and NLRP3 inflammasome activation.
    Virus Res. 2026;363:199672.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »